Anti-Tumor Effect of Bisphosphonates: a New Therapeutic Perspective
Autor(a) principal: | |
---|---|
Data de Publicação: | 2004 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Brasileira de Cancerologia (Online) |
Texto Completo: | https://rbc.inca.gov.br/index.php/revista/article/view/2058 |
Resumo: | Bisphosphonates are potent osteoclast-mediated bone reabsorption inhibitors. These drugs are effective in reducing serum calcium levels in patients with malignant hypercalcaemia, as well as in bone pain, osteoporosis and bone metastasis treatment. Several studies have demonstrated that bisphosphonates are effective in other cell types than osteoclasts. In tumour cells they can act inducing apoptosis, inhibiting cell proliferation, inhibiting cell adhesion and invasion or bone metastasis. The underlying molecular mechanism to these effects seems to be the inhibition of mevalonate pathway enzymes, which leads to a prenilation impairment of GTPases like Ras and Rho, important in maintaining cellular cytoskeleton integrity and vesicles trafficking. Evidences from recent laboratorial and clinical studies suggest that bisphosphonates have an important role as a supplemental, and possibly as complementary treatment in cancer therapy. A more complete understanding concerning the anti-tumor effect of these drugs may suggest new and selective therapeutical possibilities. |
id |
INCA-1_a1760f6893ce6b6a861538aecf01a757 |
---|---|
oai_identifier_str |
oai:rbc.inca.gov.br:article/2058 |
network_acronym_str |
INCA-1 |
network_name_str |
Revista Brasileira de Cancerologia (Online) |
repository_id_str |
|
spelling |
Anti-Tumor Effect of Bisphosphonates: a New Therapeutic PerspectiveEfeito Anti-Tumoral dos Bisfosfonatos: uma Nova Perspectiva TerapêuticaEfeito Anti-TumoralBisfosfonatosMetástasesApoptoseAnti-Tumor EffectBisphosphonatesMetastasisApoptosisBisphosphonates are potent osteoclast-mediated bone reabsorption inhibitors. These drugs are effective in reducing serum calcium levels in patients with malignant hypercalcaemia, as well as in bone pain, osteoporosis and bone metastasis treatment. Several studies have demonstrated that bisphosphonates are effective in other cell types than osteoclasts. In tumour cells they can act inducing apoptosis, inhibiting cell proliferation, inhibiting cell adhesion and invasion or bone metastasis. The underlying molecular mechanism to these effects seems to be the inhibition of mevalonate pathway enzymes, which leads to a prenilation impairment of GTPases like Ras and Rho, important in maintaining cellular cytoskeleton integrity and vesicles trafficking. Evidences from recent laboratorial and clinical studies suggest that bisphosphonates have an important role as a supplemental, and possibly as complementary treatment in cancer therapy. A more complete understanding concerning the anti-tumor effect of these drugs may suggest new and selective therapeutical possibilities.Os bisfosfonatos (BFs) são potentes inibidores da reabsorção óssea mediada por osteoclastos. Essas drogas são efetivas na redução do cálcio sérico em pacientes com hipercalcemia maligna, assim como também no tratamento da dor óssea, osteoporose e metástases ósseas. Diversos estudos demonstram que os BFs possuem efeito em outras células além dos osteoclastos. Em células tumorais podem agir induzindo a apoptose, inibindo a proliferação celular, inibindo a adesão e a invasividade celular ou as metástases ósseas. O mecanismo molecular subjacente a estes efeitos parece ser a inibição de enzimas da via do mevalonato, o que leva a um impedimento da prenilação de GTPases como Ras e Rho, importantes para a manutenção da integridade do citoesqueleto e tráfego de vesículas nas células. As evidências dos recentes estudos laboratoriais e clínicos sugerem que os BFs têm um papel importante como tratamento suplementar e possivelmente complementar na terapia do câncer. Um entendimento mais profundo e completo sobre o efeito anti-tumoral destas drogas pode sugerir possibilidades terapêuticas novas e seletivas.INCA2004-03-31info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisão de literaturaapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/205810.32635/2176-9745.RBC.2004v50n1.2058Revista Brasileira de Cancerologia; Vol. 50 No. 1 (2004): Jan./Feb./Mar.; 45-54Revista Brasileira de Cancerologia; Vol. 50 Núm. 1 (2004): ene./feb./mar.; 45-54Revista Brasileira de Cancerologia; v. 50 n. 1 (2004): jan./fev./mar.; 45-542176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/2058/1276Vasconcellos, Déborah V.Duarte, Maria Eugenia L.Maia, Raquel C.info:eu-repo/semantics/openAccess2021-11-29T20:33:49Zoai:rbc.inca.gov.br:article/2058Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:33:49Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false |
dc.title.none.fl_str_mv |
Anti-Tumor Effect of Bisphosphonates: a New Therapeutic Perspective Efeito Anti-Tumoral dos Bisfosfonatos: uma Nova Perspectiva Terapêutica |
title |
Anti-Tumor Effect of Bisphosphonates: a New Therapeutic Perspective |
spellingShingle |
Anti-Tumor Effect of Bisphosphonates: a New Therapeutic Perspective Vasconcellos, Déborah V. Efeito Anti-Tumoral Bisfosfonatos Metástases Apoptose Anti-Tumor Effect Bisphosphonates Metastasis Apoptosis |
title_short |
Anti-Tumor Effect of Bisphosphonates: a New Therapeutic Perspective |
title_full |
Anti-Tumor Effect of Bisphosphonates: a New Therapeutic Perspective |
title_fullStr |
Anti-Tumor Effect of Bisphosphonates: a New Therapeutic Perspective |
title_full_unstemmed |
Anti-Tumor Effect of Bisphosphonates: a New Therapeutic Perspective |
title_sort |
Anti-Tumor Effect of Bisphosphonates: a New Therapeutic Perspective |
author |
Vasconcellos, Déborah V. |
author_facet |
Vasconcellos, Déborah V. Duarte, Maria Eugenia L. Maia, Raquel C. |
author_role |
author |
author2 |
Duarte, Maria Eugenia L. Maia, Raquel C. |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Vasconcellos, Déborah V. Duarte, Maria Eugenia L. Maia, Raquel C. |
dc.subject.por.fl_str_mv |
Efeito Anti-Tumoral Bisfosfonatos Metástases Apoptose Anti-Tumor Effect Bisphosphonates Metastasis Apoptosis |
topic |
Efeito Anti-Tumoral Bisfosfonatos Metástases Apoptose Anti-Tumor Effect Bisphosphonates Metastasis Apoptosis |
description |
Bisphosphonates are potent osteoclast-mediated bone reabsorption inhibitors. These drugs are effective in reducing serum calcium levels in patients with malignant hypercalcaemia, as well as in bone pain, osteoporosis and bone metastasis treatment. Several studies have demonstrated that bisphosphonates are effective in other cell types than osteoclasts. In tumour cells they can act inducing apoptosis, inhibiting cell proliferation, inhibiting cell adhesion and invasion or bone metastasis. The underlying molecular mechanism to these effects seems to be the inhibition of mevalonate pathway enzymes, which leads to a prenilation impairment of GTPases like Ras and Rho, important in maintaining cellular cytoskeleton integrity and vesicles trafficking. Evidences from recent laboratorial and clinical studies suggest that bisphosphonates have an important role as a supplemental, and possibly as complementary treatment in cancer therapy. A more complete understanding concerning the anti-tumor effect of these drugs may suggest new and selective therapeutical possibilities. |
publishDate |
2004 |
dc.date.none.fl_str_mv |
2004-03-31 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Revisão de literatura |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/2058 10.32635/2176-9745.RBC.2004v50n1.2058 |
url |
https://rbc.inca.gov.br/index.php/revista/article/view/2058 |
identifier_str_mv |
10.32635/2176-9745.RBC.2004v50n1.2058 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/2058/1276 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
INCA |
publisher.none.fl_str_mv |
INCA |
dc.source.none.fl_str_mv |
Revista Brasileira de Cancerologia; Vol. 50 No. 1 (2004): Jan./Feb./Mar.; 45-54 Revista Brasileira de Cancerologia; Vol. 50 Núm. 1 (2004): ene./feb./mar.; 45-54 Revista Brasileira de Cancerologia; v. 50 n. 1 (2004): jan./fev./mar.; 45-54 2176-9745 reponame:Revista Brasileira de Cancerologia (Online) instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) instacron:INCA |
instname_str |
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
instacron_str |
INCA |
institution |
INCA |
reponame_str |
Revista Brasileira de Cancerologia (Online) |
collection |
Revista Brasileira de Cancerologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
repository.mail.fl_str_mv |
rbc@inca.gov.br |
_version_ |
1797042249445408768 |